Cover Image
市場調查報告書

前列腺癌:全球醫藥品的預測與市場分析

PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 310941
出版日期 內容資訊 英文 271 Pages
訂單完成後即時交付
價格
Back to Top
前列腺癌:全球醫藥品的預測與市場分析 PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2023
出版日期: 2015年04月08日 內容資訊: 英文 271 Pages
簡介

前列腺癌是次於皮膚癌的男性最常見癌症,佔男性癌症患者整體的15%。如果預先早期發現患部,可於局部性的發病狀態內進行治療,不過,如果診斷為去勢療法無效前列腺癌 (CRPC) ,現在沒有治療選項。但,2010年之後有5種CRPC治療藥新認證。預計今後10年,有9種治療藥認證,其中8種上市。因此,全球主要國家的前列腺癌治療藥的市場規模預計增加3倍。

本報告提供全球主要9個國家的前列腺癌治療方法相關最新的研究、開發情形,和市場未來展望和分析,疾病概要和治療方法,市場機會及未滿足需求,市場規模趨勢 (今後10年份),已上市/臨床實驗中的主要治療藥簡介 (功效、安全性、市場競爭力),全球整體、各國市場的現狀與今後的方向性等資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理生理學
  • 病期分類
  • 症狀
  • 預後
  • 生活品質 (QoL)

第4章 流行病學

  • 疾病的背景
  • 風險要素和共生病症
  • 全球的趨勢
    • 美國
    • 歐洲5個國家
    • 日本、巴西、加拿大
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 前列腺癌的流行病學的預測(今後11年份):受診發病者的病例數
    • 受診的前列腺癌發病者的數量
    • 受診的前列腺癌發病者的數量:各年齡
    • 受診的前列腺癌發病者的數量 (已調整年齡)
    • 受診的前列腺癌發病者的數量:各診斷時的病期 (階段)
    • 受診的前列腺癌的5年患病人數
    • 受診的CRPC (去勢療法無效前列腺癌 ) 的5年患病人數
    • 受診的骨轉移的5年患病人數 (CRPC患者的情況)
  • 議論
    • 流行病學預測的考察
    • 分析的限制
    • 分析的優勢

第5章 疾病管理

  • 診斷、治療概要
    • 篩檢、診斷
    • 治療指南主要的處方藥
    • 臨床診療
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 巴西
  • 加拿大

第6章 競爭評估

  • 概要
  • 產品簡介:領導品牌、標靶治療
    • Zytiga (abiraterone acetate)
    • Xtandi (Enzalutamide)
    • Xofigo (氯化鐳-223)
  • 產品簡介:領導品牌,化療
    • Jevtana (cabazitaxel)
  • 產品簡介:領導品牌,治療疫苗
    • Provenge (Sipuleucel-T)
  • 產品簡介:領導品牌,荷爾蒙療法
    • Zoladex (goserelin acetate)
    • Lupron Depot (leuprolide acetate)
    • Eligard (leuprolide acetate)
    • Trelstar (triptorelin acetate)
    • Firmagon (degarelix)
    • Casodex (bicalutamide)
  • 產品簡介:領導品牌,骨治療
    • Zometa (zoledronic acid)
    • Xgeva (denosumab)

第7章 未滿足需求及機會

  • 概要
  • 對mCRPC (轉移性的CRPC) 患者有生存效果的治療方法
    • 未滿足需求
    • 差距分析
    • 市場機會
  • 非mCRPC患者治療選擇
  • 為了預見對Zytiga、Xtandi有抵抗性的生物標記識別
  • 為了管理mCRPC的最適合的投藥時期的識別

第8章 開發平台評估

  • 概要
  • 產品簡介:免疫療法
    • Yervoy (Ipilimumab)
    • ProstVac
    • ProstAtak
    • DCVAC/PCa
    • ITK1
  • 產品簡介:標靶治療
    • Custirsen Sodium
    • Tasquinimod
    • ARN-509
    • ODM-201

第9章 現在及未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Astellas Pharma Inc.
    • Johnson & Johnson
    • Bayer

第10章 市場預測

  • 全球市場
    • 預測
    • 推進因素及障礙 : 全球問題
  • 美國
    • 預測
    • 近幾年的主要趨勢
    • 推動、阻礙因素
  • 歐洲5個國家
  • 日本
  • 巴西
  • 加拿大

第11章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC96PIDR

Prostate cancer is the second most common cancer in men worldwide, after skin cancer. It accounts for 15% of all the cancers diagnosed in men, and thus represents a huge burden on healthcare systems. While patients diagnosed with early-stage, localized prostate cancer can be cured, patients who are diagnosed with or progress to castration-resistant prostate cancer (CRPC) have no curative options. This report focuses on the current treatment landscape, unmet needs, pipeline assessment and market outlook for prostate cancer. Since 2010, five new drugs have been approved for the treatment of CRPC: Dendreon's Provenge, Sanofi's Jevtana, Johnson & Johnson's Zytiga, Medivation/Astellas' Xtandi, and Bayer's Xofigo. During the forecast period from 2013-2023, GlobalData expects that nine new late-stage pipeline agents will launch, eight of which will be for the treatment of CRPC. As a result of this unprecedented level of clinical development, GlobalData predicts there will be massive changes in the CRPC treatment paradigm. In addition, due to the influx of new therapies, the size of the prostate cancer market across the nine major pharmaceutical markets (9MM) (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and Canada) will increase three-fold.

Highlights

Key Questions Answered

  • How will prostate cancer disease management change as new agents enter the market?
  • Which prostate cancer patients have the greatest unmet needs and how well will these needs be addressed by the new agents?
  • What are the most dominant players in the prostate cancer space and what corporate strategies are pursued by these companies?
  • What are the most promising late-stage pipeline agents for prostate cancer? How do they compare to currently marketed products?
  • What opportunities will remain for future players following the launch of these pipeline agents?

Key Findings

  • The prostate cancer market, in the 9MM is forecasted to rapidly increase from $2.6bn in 2013 to $8.3bn in 2023, at a CAGR of 12.4%. This growth will be driven by the label extensions of currently marketed drugs as well as the launch of nine new premium-priced therapies for the treatment of prostate cancer.
  • GlobalData expects Medivation and Astellas' Xtandi will become the market leader in prostate cancer. Xtandi is currently approved for pre- and post-chemotherapy metastatic castration-resistant prostate cancer (CRPC). Over the course of the forecast period, GlobalData anticipates it will receive label extensions in non-metastatic CRPC and hormone-sensitive prostate cancer, making it available to virtually all prostate cancer patients segments, with the exception of those with localized disease.
  • The prostate cancer pipeline is robust with nine drugs in late-stage development. While androgen biosynthesis is still a major target, many of the pipeline candidates have diverse mechanisms of action and target proteins and pathways that are not targeted by the currently marketed prostate cancer treatments. Among these new candidates are a checkpoint inhibitor, a clusterin inhibitor, and an anti-angiogenic agent. There are also several vaccines, both autologous and off-the-shelf, that have a significant presence in this pipeline.

Scope

  • Overview of prostate cancer, including epidemiology, etiology, pathophysiology, clinical staging, symptoms, prognosis, quality of life, and disease management.
  • Annualized prostate cancer therapeutics market revenue from 2013-2023. Annual cost of therapy, and major marketed and pipeline drug sales in this forecast period are included.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the prostate cancer therapeutics market.
  • Pipeline analysis: The prostate cancer pipeline is robust with many late-stage candidates set to launch in the forecast period. Comprehensive analysis of the nine most promising candidates in Phase III development are highlighted and profiled.
  • Analysis of the current and future market competition in the global prostate cancer therapeutics market, including insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the 9MM prostate cancer market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 9MM prostate cancer therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Staging
  • 3.3. Symptoms
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. US
    • 4.3.2. 5EU
    • 4.3.3. Japan, Brazil, and Canada
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods
  • 4.5. Epidemiological Forecast for Prostate Cancer (2013-2023)
    • 4.5.1. Diagnosed Incident Cases of Prostate Cancer
    • 4.5.2. Age-Specific Diagnosed Incident Cases of Prostate Cancer
    • 4.5.3. Age-Standardized Diagnosed Incidence of Prostate Cancer
    • 4.5.4. Clinical Stage at Diagnosis
    • 4.5.5. Diagnosed Five-Year Prevalent Cases of Prostate Cancer
    • 4.5.6. Diagnosed Five-Year Prevalent Cases of CRPC
    • 4.5.7. Diagnosed Five-Year Prevalent Cases of Bone Metastases Among CRPC Patients
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Screening and Diagnosis
    • 5.1.2. Treatment Guidelines and the Leading Prescribed Drugs
    • 5.1.3. Clinical Practice
  • 5.2. US
  • 5.3. France
  • 5.4. Germany
  • 5.5. Italy
  • 5.6. Spain
  • 5.7. UK
  • 5.8. Japan
  • 5.9. Brazil
  • 5.10. Canada

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles - Major Brands, Targeted Therapies
    • 6.2.1. Zytiga (abiraterone acetate)
    • 6.2.2. Xtandi (enzalutamide)
    • 6.2.3. Xofigo (radium 223 dichloride)
  • 6.3. Product Profiles - Major Brands, Chemotherapies
    • 6.3.1. Jevtana (cabazitaxel)
  • 6.4. Product Profiles - Major Brands, Therapeutic Vaccines
    • 6.4.1. Provenge (sipuleucel-T)
  • 6.5. Product Profiles - Major Brands, Hormone Therapies
    • 6.5.1. Zoladex (goserelin acetate)
    • 6.5.2. Lupron Depot (leuprolide acetate)
    • 6.5.3. Eligard (leuprolide acetate)
    • 6.5.4. Trelstar (triptorelin acetate)
    • 6.5.5. Firmagon (degarelix)
    • 6.5.6. Casodex (bicalutamide)
  • 6.6. Product Profiles - Major Brands, Bone Therapies
    • 6.6.1. Zometa (zoledronic acid)
    • 6.6.2. Xgeva (denosumab)

7. Unmet Need and Opportunity

  • 7.1. Overview
  • 7.2. Therapies That Provide a Durable Overall Survival Benefit for mCRPC Patients
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Therapeutic Options for nmCRPC Patients
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Identification of Biomarkers to Predict Zytiga and Xtandi Resistance
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Defining the Best Sequence of Drugs to Manage mCRPC
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Product Profiles - Immunotherapies
    • 8.2.1. Yervoy (ipilimumab)
    • 8.2.2. ProstVac
    • 8.2.3. ProstAtak
    • 8.2.4. DCVAC/PCa
    • 8.2.5. ITK1
  • 8.3. Product Profiles - Targeted Therapies
    • 8.3.1. Custirsen Sodium
    • 8.3.2. Tasquinimod
    • 8.3.3. ARN-509
    • 8.3.4. ODM-201

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Astellas
    • 9.3.2. Johnson & Johnson
    • 9.3.3. Bayer

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. 5EU
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Japan
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Brazil
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. Canada
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed Prostate Cancer Patients
    • 11.4.2. Percentage Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Pricing of Pipeline Agents
  • 11.5. Primary Research - KOLs Interviewed for This Report
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analyst
    • 11.7.2. Director of Oncology
    • 11.7.3. Epidemiologist
    • 11.7.4. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: TNM Classification of Prostate Cancer
  • Table 2: Prostate Cancer Staging
  • Table 3: Risk-Group Classifications Used in Prostate Cancer
  • Table 4: Risk Factors and Comorbidities for Prostate Cancer
  • Table 5: 9MM, Sources of Prostate Cancer Diagnosed Incidence Data
  • Table 6: 9MM, Sources of Data for the Clinical Stage of Prostate Cancer at Diagnosis
  • Table 7: 9MM, Sources of Prostate Cancer Diagnosed Five-Year Prevalent Cases Data
  • Table 8: 9MM, Sources of CRPC Diagnosed Five-Year Prevalent Cases Data
  • Table 9: 9MM, Diagnosed Incident Cases of Prostate Cancer, Ages ≥40 Years, N, 2013-2023
  • Table 10: 9MM, Age-Specific Diagnosed Incident Cases of Prostate Cancer, N, Row (%), 2013
  • Table 11: 9MM, Diagnosed Five-Year Prevalent Cases of Prostate Cancer, Ages ≥40 Years, 2013-2023
  • Table 12: 9MM, Diagnosed Five-Year Prevalent Cases of CRPC, Ages ≥40 Years, 2013-2023
  • Table 13: 9MM, Diagnosed Five-Year Prevalent Cases of Bone Metastases Among CRPC Patients, Ages ≥40 Years, 2013-2023
  • Table 14: Most Commonly Used Treatment Guidelines for Prostate Cancer, 2014
  • Table 15: Most Commonly Prescribed Hormonal Therapies for Prostate Cancer, 2014
  • Table 16: Most Commonly Prescribed Chemotherapeutic, Drug, and Bone Therapies for CRPC, 2014
  • Table 17: Diagnosis and Treatment of Prostate Cancer, Country Profile - US
  • Table 18: Diagnosis and Treatment of Prostate Cancer, Country Profile - France
  • Table 19: Diagnosis and Treatment of Prostate Cancer, Country Profile - Germany
  • Table 20: Diagnosis and Treatment of Prostate Cancer, Country Profile - Italy
  • Table 21: Diagnosis and Treatment of Prostate Cancer, Country Profile - Spain
  • Table 22: Diagnosis and Treatment of Prostate Cancer, Country Profile - UK
  • Table 23: Diagnosis and Treatment of Prostate Cancer Country Profile - Japan
  • Table 24: Diagnosis and Treatment of Prostate Cancer, Country Profile - Brazil
  • Table 25: Diagnosis and Treatment of Prostate Cancer, Country Profile - Canada
  • Table 26: Leading Branded Drugs Used to Treat Prostate Cancer, 2014
  • Table 27: Product Profile - Zytiga
  • Table 28: Zytiga SWOT Analysis, 2014
  • Table 29: Global Sales Forecasts ($m) for Zytiga, 2013-2023
  • Table 30: Product Profile - Xtandi
  • Table 31: Xtandi SWOT Analysis, 2014
  • Table 32: Global Sales Forecasts ($m) for Xtandi, 2013-2023
  • Table 33: Product Profile - Xofigo
  • Table 34: Xofigo SWOT Analysis, 2014
  • Table 35: Global Sales Forecasts ($m) for Xofigo, 2013-2023
  • Table 36: Product Profile - Jevtana
  • Table 37: Jevtana SWOT Analysis, 2014
  • Table 38: Global Sales Forecasts ($m) for Jevtana, 2013-2023
  • Table 39: Product Profile - Provenge
  • Table 40: Provenge SWOT Analysis, 2014
  • Table 41: Global Sales Forecasts ($m) for Provenge, 2013-2023
  • Table 42: Product Profile - Zoladex
  • Table 43: Zoladex SWOT Analysis, 2014
  • Table 44: Product Profile - Lupron
  • Table 45: Lupron SWOT Analysis, 2014
  • Table 46: Product Profile - Eligard
  • Table 47: Eligard SWOT Analysis, 2014
  • Table 48: Product Profile - Trelstar
  • Table 49: Trelstar SWOT Analysis, 2014
  • Table 50: Product Profile - Firmagon
  • Table 51: Firmagon SWOT Analysis, 2014
  • Table 52: Product Profile - Casodex
  • Table 53: Casodex SWOT Analysis, 2014
  • Table 54: Product Profile - Zometa
  • Table 55: Zometa SWOT Analysis, 2014
  • Table 56: Product Profile - Xgeva
  • Table 57: Xgeva SWOT Analysis, 2014
  • Table 58: Unmet Need and Opportunity in Prostate Cancer
  • Table 59: Drugs in Phase III Clinical Trials for Prostate Cancer
  • Table 60: Product Profile - Yervoy
  • Table 61: Yervoy SWOT Analysis, 2014
  • Table 62: Global Sales Forecasts ($m) for Yervoy, 2013-2023
  • Table 63: Product Profile - ProstVac
  • Table 64: ProstVac SWOT Analysis, 2014
  • Table 65: Global Sales Forecasts ($m) for ProstVac, 2013-2023
  • Table 66: Product Profile - ProstAtak
  • Table 67: ProstAtak SWOT Analysis, 2014
  • Table 68: Global Sales Forecasts ($m) for ProstAtak, 2013-2023
  • Table 69: Product Profile - DCVAC/PCa
  • Table 70: DCVAC/PCa SWOT Analysis, 2014
  • Table 71: Global Sales Forecasts ($m) for DCVAC, 2013-2023
  • Table 72: Product Profile - ITK1
  • Table 73: ITK1 SWOT Analysis, 2014
  • Table 74: Global Sales Forecasts ($m) for ITK1, 2013-2023
  • Table 75: Product Profile - Custirsen Sodium
  • Table 76: Custirsen Sodium SWOT Analysis, 2014
  • Table 77: Global Sales Forecasts ($m) for Custirsen Sodium, 2013-2023
  • Table 78: Product Profile - Tasquinimod
  • Table 79: Tasquinimod SWOT Analysis, 2014
  • Table 80: Global Sales Forecasts ($m) for Tasquinimod, 2013-2023
  • Table 81: Product Profile - ARN-509
  • Table 82: ARN-509 SWOT Analysis, 2014
  • Table 83: Global Sales Forecasts ($m) for ARN-509, 2013-2023
  • Table 84: Product Profile - ODM-201
  • Table 85: ODM-201 SWOT Analysis, 2014
  • Table 86: Global Sales Forecasts ($m) for ODM-201, 2013-2023
  • Table 87: Key Companies in the Prostate Cancer Market in the 9MM, 2014
  • Table 88: Astellas' Prostate Cancer Portfolio Assessment, 2014
  • Table 89: J&J's Prostate Cancer Portfolio Assessment, 2014
  • Table 90: Bayer's Prostate Cancer Portfolio Assessment, 2014
  • Table 91: Global Sales Forecasts ($m) for Prostate Cancer, 2013-2023
  • Table 92: Global Prostate Cancer Market - Drivers and Barriers, 2013-2023
  • Table 93: Sales Forecasts ($m) for Prostate Cancer in the US, 2013-2023
  • Table 94: Key Events Impacting Sales for Prostate Cancer in the US, 2013-2023
  • Table 95: US Prostate Cancer Market - Drivers and Barriers, 2013-2023
  • Table 96: Sales Forecasts ($m) for Prostate Cancer in the 5EU, 2013-2023
  • Table 97: Key Events Impacting Sales for Prostate Cancer in the 5EU, 2013-2023
  • Table 98: 5EU Prostate Cancer Market - Drivers and Barriers, 2013-2023
  • Table 99: Sales Forecasts ($m) for Prostate Cancer in Japan, 2013-2023
  • Table 100: Key Events Impacting Sales for Prostate Cancer in Japan, 2013-2023
  • Table 101: Japan Prostate Cancer Market - Drivers and Barriers, 2013-2023
  • Table 102: Sales Forecasts ($m) for Prostate Cancer in Brazil, 2013-2023
  • Table 103: Key Events Impacting Sales for Prostate Cancer in Brazil, 2013-2023
  • Table 104: Brazil Prostate Cancer Market - Drivers and Barriers, 2013-2023
  • Table 105: Sales Forecasts ($m) for Prostate Cancer in Canada, 2013-2023
  • Table 106: Key Events Impacting Sales for Prostate Cancer in Canada, 2013-2013
  • Table 107: Canada Prostate Cancer Market - Drivers and Barriers, 2013-2023
  • Table 108: Key Launch Dates, Marketed and Pipeline Prostate Cancer Drugs
  • Table 109: Key Patent Expiration or Loss of Market Exclusivity Dates, Marketed Prostate Cancer Drugs
  • Table 110: Average Body Weight and Surface Area Across the 9MM
  • Table 111: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: 9MM, Historical Age-Standardized Prostate Cancer Diagnosed Incidence (Cases per 100,000 Population), 1998-2007
  • Figure 2: 9MM, Diagnosed Incident Cases of Prostate Cancer, Ages ≥40 Years, N, 2013-2023
  • Figure 3: 9MM, Age-Specific Diagnosed Incident Cases of Prostate Cancer, N, 2013
  • Figure 4: 9MM, Age-Standardized Diagnosed Incidence of Prostate Cancer, Ages ≥40 Years, 2013
  • Figure 5: 9MM, Percentage Distribution of Incident Cases of Prostate Cancer By Clinical Stage at Diagnosis, Ages ≥40 Years
  • Figure 6: 9MM, Diagnosed Five-Year Prevalent Cases of Prostate Cancer, Ages ≥40 Years, 2013-2023
  • Figure 7: 9MM, Diagnosed Five-Year Prevalent Cases of CRPC, Ages ≥40 Years, 2013-2023
  • Figure 8: 9MM, Diagnosed Five-Year Prevalent Cases of Bone Metastases Among CRPC Patients, Ages ≥40 Years, 2013-2023
  • Figure 9: Disease Management Flowchart for Prostate Cancer
  • Figure 10: Competitive Assessment of Late-Stage Pipeline Agents in Prostate Cancer, 2013-2023
  • Figure 11: Yervoy's Clinical Development
  • Figure 12: Potential Clinical and Commercial Positioning of Yervoy
  • Figure 13: ProstVac's Clinical Development
  • Figure 14: Potential Clinical and Commercial Positioning of ProstVac
  • Figure 15: ProstAtak's Clinical Development
  • Figure 16: Potential Clinical and Commercial Positioning of ProstAtak
  • Figure 17: DCVAC/PCa's Clinical Development
  • Figure 18: Potential Clinical and Commercial Positioning of DCVAC/PCa
  • Figure 19: ITK1's Clinical Development
  • Figure 20: Potential Clinical and Commercial Positioning of ITK1
  • Figure 21: Custirsen Sodium's Clinical Development
  • Figure 22: Potential Clinical and Commercial Positioning of Custirsen Sodium
  • Figure 23: Tasquinimod's Clinical Development
  • Figure 24: Potential Clinical and Commercial Positioning of Tasquinimod
  • Figure 25: ARN-509's Clinical Development
  • Figure 26: Potential Clinical and Commercial Positioning of ARN-509
  • Figure 27: ODM-201's Clinical Development
  • Figure 28: Potential Clinical and Commercial Positioning of ODM-201
  • Figure 29: Company Portfolio Gap Analysis in Prostate Cancer, 2013-2023
  • Figure 30: Global Sales for Prostate Cancer by Region, 2013-2023
  • Figure 31: Sales for Prostate Cancer in the US by Drug Class, 2013-2023
  • Figure 32: Sales for Prostate Cancer in the 5EU by Drug Class, 2013-2023
  • Figure 33: Sales for Prostate Cancer in Japan by Drug Class, 2023
  • Figure 34: Sales for Prostate Cancer in Brazil by Drug Class, 2013-2023
  • Figure 35: Sales for Prostate Cancer in Canada by Drug Class, 2013-2023
Back to Top